Orphalan, a global pharmaceutical company specializing in orphan drugs, has acquired ORPHELIA Pharma, a French pharmaceutical company, for an undisclosed amount. The acquisition marks a significant consolidation within the rare disease sector, bringing together two entities focused on underserved patient populations.
ORPHELIA Pharma, based in Paris and Lyon, focuses on developing and marketing medicines for pediatric orphan diseases. Its mission is centered on providing essential products in epilepsy and pediatric oncology, with formulations specifically adapted for children. The company currently has one drug approved in the European Union and another product in late-stage clinical development, complemented by recent regional agreements established across the European Union, the USA, and China.
This strategic acquisition allows Orphalan to significantly expand its product portfolio and pipeline in the critical area of pediatric rare diseases. Orphalan, known for its global development and commercialization of orphan drugs, will integrate ORPHELIA Pharma's specialized expertise in pediatric formulations and its existing market presence. Expected synergies include enhanced research and development capabilities, broader market access for existing and future therapies, and a strengthened position in the overall orphan drug market.
The combination of Orphalan’s global reach and commercialization infrastructure with ORPHELIA Pharma’s targeted pipeline in pediatric neurology and oncology is anticipated to accelerate the availability of much-needed treatments. The combined entity aims to further its impact on rare disease communities by delivering innovative and accessible solutions to children worldwide.